Kevin W Garey

Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical isolates: impact of bacterial strain and antibiotic concentration.

Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases.

Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model.

Markers of inflammation in exhaled breath condensate of young healthy smokers.

Involvement of immunization-certified pharmacists with immunization activities.

Economic consequences of unused medications in Houston, Texas.

Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.

Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone.

Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant enterococcus colonization.

An integrated pharmacoeconomic approach to antimicrobial formulary decision-making.

Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study.

Prevalence of diarrhea at a university hospital and association with modifiable risk factors.

Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.

Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections.

Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis.

Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia.

Pharmacists' perceptions of the effectiveness of antimicrobial control programs.

Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines.

Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study.

Pharmacist-managed vaccination program increased influenza vaccination rates in cardiovascular patients enrolled in a secondary prevention lipid clinic.

High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis.

Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa.

Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea.

Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.

Pharmacokinetic/Pharmacodynamic antimicrobial individualization and optimization strategies.

Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study.

Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.

Economic benefit of appropriate timing of vancomycin prophylaxis in patients undergoing cardiovascular surgery.

Peripartum Clostridium difficile infection: case series and review of the literature.

Increased bacterial adherence and biomass in Pseudomonas aeruginosa bacteria exposed to clarithromycin.

Significant publications on infectious diseases pharmacotherapy in 2007.

Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia.

WITHDRAWN: In vitro activity of rifaximin and rifampin against clinical isolates of clostridium difficile in houston, texas.

Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital.

Clostridium difficile-related death rates in Texas 1999-2005.

Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa.

Symposium on roles of and cooperation between academic- and practice-based pharmacy clinicians.

Crofelemer, a novel agent for treatment of secretory diarrhea.

Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.

Future novel therapeutic agents for Clostridium difficile infection.

Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes.

Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections.

Significant publications on infectious diseases pharmacotherapy in 2009.

Clostridium difficile infection: an emerging epidemic with more questions than answers.

Mathematical modeling to characterize the inoculum effect.

A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection.

Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy.

Risk factors for vitamin D deficiency in HIV-infected patients in the south central United States.

Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection.

A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection.

Improving patient care through implementation of an antimicrobial stewardship program.

Crofelemer for the treatment of secretory diarrhea.

In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases.

A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs.

Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia.

Evaluation of a daptomycin dose-optimization protocol.

Inhibition of biofilm formation by esomeprazole in Pseudomonas aeruginosa and Staphylococcus aureus.

Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.

Treatment of Candida famata bloodstream infections: case series and review of the literature.

Pilot of a patient-centered pharmacy practice model.

Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area.

Impact of a pharmacotherapy alerting system on medication errors.

Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile.

Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS.

Comparison of the T2Dx instrument with T2Candida assay and automated blood culture in the detection of Candida species using seeded blood samples.

A blueprint for transitioning pharmacy residents into successful clinical faculty members in colleges and schools of pharmacy.

Colonic immunopathogenesis of Clostridium difficile infections.

Investigation of potentially pathogenic Clostridium difficile contamination in household environs.

Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics.

Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates.

FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.

Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: A randomized, double-blind, placebo-controlled pilot study.

Education, training, and academic experience of newly hired, first-time pharmacy faculty members.

Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas.

Host factors and clinical outcomes of Candida colonization in critically ill patients.

Agreement among measurements and estimations of glomerular filtration in children with cancer.

Assessment of Antimicrobial Stewardship Activities in a Large Metropolitan Area.

Real-world performance of a microarray-based rapid diagnostic for Gram-positive bloodstream infections and potential utility for antimicrobial stewardship.

T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial.

Echinocandin use in hospitalized patients: a multi-institutional study.

Evaluation of portability and cost of a fluorescent PCR ribotyping protocol for Clostridium difficile epidemiology.

Expansion of clinical pharmacy through increased use of outpatient pharmacists for anticoagulation services.

Identification of toxemia in patients with Clostridium difficile infection.

A Multi-Center Prospective Derivation and Validation of a Clinical Prediction Tool for Severe Clostridium difficile Infection.

Multiplex Real-Time PCR Method for Simultaneous Identification and Toxigenic Type Characterization of Clostridium difficile From Stool Samples.

Reply to Bauer and Goff.

Pharmacy Practice Model Initiative task force report: Improving participation in a survey on hospital pharmacy practices in Texas.

Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates.

Dispensing inhalers to patients with chronic obstructive pulmonary disease on hospital discharge: Effects on prescription filling and readmission.

Age-Stratified Treatment Response Rates in Hospitalized Patients with Clostridium difficile Infection Treated with Metronidazole.

In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent.

Frequency of and risk factors for medication errors by pharmacists during order verification in a tertiary care medical center.

Oral Glutamine in Preventing Treatment-Related Mucositis in Adult Patients With Cancer: A Systematic Review.

Evaluating pharmacy leader development through the seven action logics.

Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire.

Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection.

Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes.

A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin.

A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile.

Benchmarking and medication error rates.

Ridinilazole: a novel therapy for Clostridium difficile infection.

A multi-center study of fidaxomicin use for Clostridium difficile infection.

Novel antibiotics in development to treat Clostridium difficile infection.

Association between health literacy and 30-day healthcare use after hospital discharge in the heart failure population.

Cadazolid for the treatment of Clostridium difficile.

Effect of a Healthcare-system Respiratory Fluoroquinolone Restriction Program to Alter Utilization and Impact Rates of C. difficile Infection.

Community Environmental Contamination of Toxigenic Clostridium difficile.